Evidence map›Paper›PMID 32541923›Full record

ReviewNature reviews. Rheumatology2020

Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.

Mats Dehlin, Lennart Jacobsson, Edward Roddy

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 704 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
704citing papers in PubMed, 7 pooled it
84.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06084585 naunknown statusnot on this mapstarted 2023, after this paper: background citation

A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

TypeinterventionalSponsorAmway (China) R&D CenterRan2023 to 2024Enrolled180ConditionsHyperuricemiaArmsStudy Product A (High-dose 2X), Study Product B (Low-dose X), Placebo
NCT07061587 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Developing A Gout Action Plan in Primary Care Setting in Singapore

TypeinterventionalSponsorSingHealth PolyclinicsRan2025 to 2027Enrolled72ConditionsGout, Hyperuricemia, Gout Flare, Gout ChronicArmsGout action plan
3 · Its place in the literature

Who cites it

704 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,297 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

644 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mats DehlinDepartment of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Lennart JacobssonDepartment of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-4402-148X
Edward RoddyPrimary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Keele, UK. e.roddy@keele.ac.uk.ORCID http://orcid.org/0000-0002-8954-7082
University of Gothenburg · SEMidlands Partnership NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elevation of serum urate levels resulting in supersaturation of body tissues with urate, leads to the formation and deposition of monosodium urate crystals in and around the joints. Recent reports of the prevalence and incidence of gout vary widely according to the population studied and methods employed but range from a prevalence of <1% to 6.8% and an incidence of 0.58-2.89 per 1,000 person-years. Gout is more prevalent in men than in women, with increasing age, and in some ethnic groups. Despite rising prevalence and incidence, suboptimal management of gout continues in many countries. Typically, only a third to half of patients with gout receive urate-lowering therapy, which is a definitive, curative treatment, and fewer than a half of patients adhere to treatment. Many gout risk factors exist, including obesity, dietary factors and comorbid conditions. As well as a firmly established increased risk of cardiovascular disease and chronic kidney disease in those with gout, novel associations of gout with other comorbidities have been reported, including erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporosis and venous thromboembolism. Discrete patterns of comorbidity clustering in individuals with gout have been described. Increasing prevalence and incidence of obesity and comorbidities are likely to contribute substantially to the rising burden of gout.

Indexed as

AdultAgedCase-Control StudiesComorbidityEthnicityFemaleGoutGout SuppressantsHumansHyperuricemiaIncidenceMaleMiddle AgedObesityPrevalenceRisk FactorsGout SuppressantsUric Acid

Identifiers

PMID32541923
OpenAlexW3034280373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.